Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript
Alamar Biosciences (ALMR) reported Q2 2026 revenue of $29.4M, up 82% YoY, with gross margin at 60%. Consumables rose 147% to $15.5M and instrument revenue rose 35% to $7.8M. Net loss was $13.2M. Cash was $256.3M. Full-year 2026 revenue guidance is $116M to $120M and management targets 100+ new instruments.
How this was made
The 30-second read
Why it matters
Traders can update models around FY2026 revenue growth, gross margin trajectory, and the timing risk embedded in instrument pull-through and manufacturing scale-up.
Market read
The call combines quarterly financials with explicit FY guidance and operational KPIs (installed base, pull-through, TAP), which can drive near-term repricing.
What to watch
Installed-base growth depends on instrument placements, and the pull-through metric is explicitly expected to fluctuate as placements outpace installed-base size.
Background
Alamar is scaling its ARGO HT instrument platform and consumables, with Technology Access Program (TAP) used as a leading indicator for future hardware purchases.
Ticker impact
Alamar reported Q2 revenue of $29.4M, 60% gross margin, and guided full-year 2026 revenue to $116M-$120M.
Likely positive bias if investors focus on 59% FY growth guidance and gross margin expansion, but expect volatility from rising opex and pull-through/margin fluctuation commentary.
The article includes multiple new, decision-relevant datapoints: quarterly results, FY guidance range, installed-base and pull-through targets, and a new $100M revolving credit facility.
Market effects
Signals continued demand for multiplex proteomics consumables and platform scaling, relevant to biotech tools and diagnostics sentiment.
Americas-heavy revenue mix (69%) suggests US/NA research funding and cohort-study demand are key drivers.
EMEA and APAC are smaller but growing components, implying international expansion remains a secondary lever.
Counterpoint
Despite strong top-line growth, the company’s operating expenses nearly doubled and management flagged near-term pull-through and gross margin fluctuations, which can cap multiple expansion.
Key entities
- companyAlamar Biosciences, Inc.
Reported Q2 2026 results, provided FY2026 revenue guidance, and discussed ARGO HT scaling and TAP-led funnel.
- executiveYuling Luo
CEO who discussed platform strategy and product positioning, including the blood-based eMTBR-tau immunoassay.
- executiveJustin McAnear
CFO who highlighted near-term pressure on pull-through and expected gross margin fluctuations.
